Celgene pays $100mm for exclusive option to buy Acetylon; option expires; Celgene later follows through
A year-and-a-half after investing $15mm in epigenetics company Acetylon Pharmaceuticals Inc., Celgene Corp. has paid $100mm up front for an exclusive option to buy the firm outright.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.